Cristin-resultat-ID: 1954977
Sist endret: 14. januar 2022, 16:31
NVI-rapporteringsår: 2021
Resultat
Vitenskapelig artikkel
2021

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

Bidragsytere:
  • Ingrid Egeland Christensen
  • Siri Lillegraven
  • Mielnik Pawel
  • Gunnstein Bakland
  • Liz Paucar Loli
  • Joseph Sexton
  • mfl.

Tidsskrift

Annals of the Rheumatic Diseases
ISSN 0003-4967
e-ISSN 1468-2060
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2021
Publisert online: 2021
Open Access

Importkilder

Scopus-ID: 2-s2.0-85124632868

Beskrivelse Beskrivelse

Tittel

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

Sammendrag

Objectives: To estimate the incidence of serious infections (SIs) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with tumour necrosis factor inhibitor (TNFi), and compare risk of SIs between patients with RA and PsA. Methods: We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results: A total of 3169 TNFi treatment courses (RA/PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions: Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure. Methods We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results A total of 3169 TNFi treatment courses (RA/ PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure.

Bidragsytere

Ingrid Egeland Christensen

  • Tilknyttet:
    Forfatter
    ved Klinikk for revmatologi poliklinikk og forskning ved Diakonhjemmet sykehus
  • Tilknyttet:
    Forfatter
    ved Ortopedisk avdeling - Ullevål ved Universitetet i Oslo

Siri Lillegraven

  • Tilknyttet:
    Forfatter
    ved Klinikk for revmatologi poliklinikk og forskning ved Diakonhjemmet sykehus

Pawel Franciszek Mielnik

Bidragsyterens navn vises på dette resultatet som Mielnik Pawel
  • Tilknyttet:
    Forfatter
    ved Medisinsk klinikk ved Helse Førde HF

Gunnstein Bakland

  • Tilknyttet:
    Forfatter
    ved Nevro-, ortopedi- og rehabiliteringsklinikken ved Universitetssykehuset Nord-Norge HF

Liz Paucar Loli

  • Tilknyttet:
    Forfatter
    ved Revmatismesykehuset AS
1 - 5 av 9 | Neste | Siste »